No Data
No Data
Express News | Diabetes Device Maker Embecta Explores Sale Amid Slowing Profits - FT
Embecta to Report Fiscal Third Quarter 2024 Financial Results
PARSIPPANY, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal
Express News | Embecta Corp : Morgan Stanley Cuts Target Price to $12.00 From $13.00
Morgan Stanley Maintains Embecta(EMBC.US) With Sell Rating, Cuts Target Price to $12
Morgan Stanley analyst Kallum Titchmarsh maintains $Embecta(EMBC.US)$ with a sell rating, and adjusts the target price from $16 to $12.According to TipRanks data, the analyst has a success rate of 53.
Morgan Stanley Lowers Price Target on Embecta to $12 From $13, Maintains Underweight Rating
06:45 AM EDT, 07/15/2024 (MT Newswires) -- Morgan Stanley Lowers Price Target on Embecta to $12 From $13, Maintains Underweight
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 100 points on Thursday.Shares of Methode Electronics, Inc. (NYSE:MEI) rose sharply during Thursday's session after the company